RAC1 and ovarian carcinoma: Inhibitors targeting RAC1 (EHop-016) and MEK (PD98059) have shown efficacy in suppressing malignant tendencies in ovarian cancer cells that overexpress TEM8 in vitro via the Rac1/Cdc42/JNK and MEK/ERK/STAT3 pathways [15].